Format

Send to

Choose Destination
Clin Drug Investig. 2014 Aug;34(8):587-91. doi: 10.1007/s40261-014-0212-3.

Preliminary, open-label, pilot study of add-on oral Δ9-tetrahydrocannabinol in chronic post-traumatic stress disorder.

Author information

1
Department of Psychiatry, Hadassah Hebrew University Medical Center, Jerusalem, Israel, pabloroitman36@gmail.com.

Abstract

BACKGROUND AND OBJECTIVES:

Many patients with post-traumatic stress disorder (PTSD) achieve but partial remission with current treatments. Patients with unremitted PTSD show high rates of substance abuse. Marijuana is often used as compassion add-on therapy for treatment-resistant PTSD. This open-label study evaluates the tolerance and safety of orally absorbable Δ(9)-tetrahydrocannabinol (THC) for chronic PTSD.

METHODS:

Ten outpatients with chronic PTSD, on stable medication, received 5 mg of Δ(9)-THC twice a day as add-on treatment.

RESULTS:

There were mild adverse effects in three patients, none of which led to treatment discontinuation. The intervention caused a statistically significant improvement in global symptom severity, sleep quality, frequency of nightmares, and PTSD hyperarousal symptoms.

CONCLUSIONS:

Orally absorbable Δ(9)-THC was safe and well tolerated by patients with chronic PTSD.

PMID:
24935052
DOI:
10.1007/s40261-014-0212-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center